Literature DB >> 8549074

Calcitonin gene-related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene-related peptide monoclonal antibody and its Fab' fragment.

K K Tan1, M J Brown, R J Hargreaves, S L Shepheard, D A Cook, R G Hill.   

Abstract

1. Calcitonin gene-related peptide (CGRP) is localized in perivascular sensory neurons and is a potent vasodilator. We investigated the utility of immunoblockade as an in vivo technique for probing the role of CGRP as an endogenous vasodilator. 2. The effects of an anti-CGRP monoclonal antibody (MAb; coded C4.19) and its Fab' fragment on CGRP-induced changes in blood pressure and skin blood flow were studied in pentobarbitone-anaesthetized rats. Antidromic skin vasodilatation in the rat hind paw was measured by laser Doppler fluxmetry. 3. The dose-response relationship for the hypotensive effect of intravenous rat alpha CGRP (r alpha CGRP) was similarly shifted rightward by MAb C4.19 IgG (1 mg/rat; intravenously) and Fab' fragment (2 mg/rat; intravenously). The C-terminal fragment of human alpha CGRP (h alpha CGRP8-37) also blocked the hypotensive effect of r alpha CGRP. 4. MAb C4.19 Fab' fragment (2 mg/rat; intravenously) and h alpha CGRP8-37 (100 nmol/kg; intravenously), but not MAb C4.19 IgG (up to 3 mg/rat; intravenously) or normal mouse Fab' fragment (2 mg/rat; intravenously), blocked the increased skin blood flow response to antidromic stimulation of the saphenous nerve. 5. The mean percentage changes in skin blood flow parameters due to MAb C4.19 Fab' fragment were significantly different from those due to normal mouse Fab' fragment (unpaired t-test; P < 0.05) but not from those due to h alpha CGRP8-37. 6. The results demonstrate the pharmacokinetic advantage of Fab' fragment over IgG for immunoblockade studies in vivo and support the role of CGRP in mediating skin vasodilatation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549074     DOI: 10.1042/cs0890565

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  2 in total

1.  CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

Authors:  J Zeller; K T Poulsen; J E Sutton; Y N Abdiche; S Collier; R Chopra; C A Garcia; J Pons; A Rosenthal; D L Shelton
Journal:  Br J Pharmacol       Date:  2008-09-08       Impact factor: 8.739

Review 2.  Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.

Authors:  Lars Edvinsson
Journal:  J Intern Med       Date:  2022-05-19       Impact factor: 13.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.